Participated · Series B · May 2026

Founded in 2015 in Shenzhen, Elegoo began with STEM education kits and entered the 3D-printing market in 2018 with its Mars resin printer, which became a market success. The company claims a leading global position in shipments of LCD resin printers and is one of four major players—alongside Bambu Lab, Creality and Anycubic—that together control roughly 90% of the entry-level market. In 2025 Elegoo reported revenue of more than 2.3 billion yuan, growing over 30% year-over-year, with over 90% of that revenue from international markets. While resin printers remain a core product, Elegoo is increasingly targeting the FDM segment and has launched the Centauri-Carbon series, including a multi-color FDM model. Leadership, including CEO Chris Hong, has publicly stated an ambition to pursue a top global position in consumer 3D printing. Recent investments from DJI and Meituan are intended to add strategic technological and distribution capabilities to support the company’s product development and market expansion.

Participated · Series A · Apr 2026

Axoft develops implantable brain-computer interfaces (iBCIs) built from its proprietary bio-inspired Fleuron™ material, designed to improve biocompatibility and neural data quality. Fleuron is reported to be up to 10,000x softer than polyimide, offers greater region access and higher sensor/stimulator density per thread, and reduces signal attenuation versus standard flexible probes. The company has demonstrated first-in-human implants in more than 11 patients and completed a study at The Panama Clinic with four patients undergoing tumor resection, recording cortical and subcortical activity. Axoft has research published in Nature (December 2023 and June 2025) showing scalable single-cell electrophysiology enabled by its materials and interfaces. The company has commercialized Fleuron via an exclusive licensing agreement with Stanford and secured a joint development agreement with Kayaku Advanced Materials, alongside grant funding to build a GMP manufacturing facility. Co-founded in 2021 and headquartered in Cambridge, Massachusetts, Axoft has opened a subsidiary in Grenoble, France, and plans to scale manufacturing and expand engineering, microfabrication and chemistry teams as it advances clinical programs and regulatory work.

Participated · Equity · Mar 2026

Earendil Labs applies AI across discovery, design, optimization, and development to generate and progress protein-based biologics programs. Its AI-native platform has produced more than 40 programs and includes HXN-1001, a half-life extended anti-TL1A antibody that the company says is ready for Phase 2 clinical development, with multiple IND submissions planned in 2026 and 2027. The company works through a combination of internal pipeline development and strategic partnerships, including a 2025 worldwide exclusive license agreement and broader strategic collaboration with Sanofi covering multiple programs. Earendil operates alongside affiliate Helixon Therapeutics and targets therapies for autoimmune diseases, cancer, and other areas of unmet medical need. With the announced $787 million financing, the company plans to scale its AI-driven R&D organization, expand scientific and engineering teams, and advance multiple internal programs toward clinical milestones.

Participated · Series C · Feb 2026

Founded in April 2020 and based in Chuo-ku, Tokyo, NOT A HOTEL provides unique villa properties created with world-class architects and creators, combining dedicated mobility options (helicopter, cruiser) and personalized services. Its offerings blend architecture, technology, and hospitality to deliver integrated stay experiences and owner-centric services. The company is expanding beyond stays into mobility via its "NOT A GARAGE" shared-ownership mobility service and seeks to link movement and destination experiences. Financially, NOT A HOTEL completed a ¥16.5 billion Series D transaction (¥10.0B primary + ¥6.5B secondary) with strategic investors including TIP, SBI Group, Sequoia, and TT Lion Partners. Going forward, the company plans to use the capital and partnerships to accelerate existing business growth, improve owner experience, and explore purchaser financing options through SBI.

Led · Series A · Feb 2026

ZAST.AI has built a code security engine that combines deep AI-based static analysis with automated proof-of-concept (PoC) generation and execution, so every vulnerability it reports is empirically verified. The system detects both traditional syntax-level issues such as SQL injection and XSS as well as harder-to-find semantic flaws like IDOR and privilege-escalation logic errors. In 2025 the platform uncovered hundreds of zero-day bugs across dozens of prominent open-source projects, earning 119 CVE numbers and prompting fixes from maintainers at Microsoft, Apache, Alibaba and others. The company already serves multiple enterprise customers, including Fortune Global 500 firms, helping them shorten remediation cycles and cut security-operation costs. Located in Seattle, ZAST.AI positions itself as an end-to-end, AI-powered security provider. The newly raised capital will fuel core technology R&D, feature expansion and a global go-to-market push. To date, the startup has amassed close to US$10 million in total funding.